Due to ‘over­whelm­ing de­mand,’ Sanofi and As­traZeneca’s RSV an­ti­body to be in lim­it­ed sup­ply 

Sanofi is ex­pect­ing sup­ply con­straints of its in­fant RSV an­ti­body Bey­for­tus, which it co-de­vel­oped with As­traZeneca, in the first quar­ter of this year. While it is ex­pect­ing to boost pro­duc­tion, the com­pa­ny says it’s too ear­ly to say by how much.

The French phar­ma is work­ing to lift any man­u­fac­tur­ing bot­tle­necks and “un­lock ca­pac­i­ty” to tack­le sup­ply con­straints, but “the ques­tion is how much progress we can make in 2024,” CEO Paul Hud­son not­ed on a me­dia call Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER